0001070081-19-000020.txt : 20190307 0001070081-19-000020.hdr.sgml : 20190307 20190307213141 ACCESSION NUMBER: 0001070081-19-000020 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190305 FILED AS OF DATE: 20190307 DATE AS OF CHANGE: 20190307 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Utter Christine Marie CENTRAL INDEX KEY: 0001707685 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35969 FILM NUMBER: 19667441 MAIL ADDRESS: STREET 1: C/O PTC THERAPEUTICS, INC. STREET 2: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PTC THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001070081 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043416587 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080-2449 BUSINESS PHONE: 9082227000 MAIL ADDRESS: STREET 1: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080-2449 FORMER COMPANY: FORMER CONFORMED NAME: PTC THERAPEUTICS INC DATE OF NAME CHANGE: 19980909 4 1 wf-form4_155201228629693.xml FORM 4 X0306 4 2019-03-05 0 0001070081 PTC THERAPEUTICS, INC. PTCT 0001707685 Utter Christine Marie C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 0 1 0 0 Principal Financial Officer Common Stock 2019-03-05 4 S 0 1509 34.78 D 5937 D Common Stock 2019-03-05 4 S 0 1000 35.25 D 4937 D Common Stock 2019-03-05 4 M 0 1150 10.85 A 6087 D Common Stock 2019-03-05 4 S 0 540 34.71 D 5547 D Common Stock 2019-03-05 4 S 0 610 35.17 D 4937 D Common Stock 2019-03-05 4 M 0 18750 13.10 A 23687 D Common Stock 2019-03-05 4 S 0 9929 34.75 D 13758 D Common Stock 2019-03-05 4 S 0 8821 35.21 D 4937 D Common Stock 2019-03-05 4 M 0 6300 11.23 A 11237 D Common Stock 2019-03-05 4 S 0 2760 34.70 D 8477 D Common Stock 2019-03-05 4 S 0 3540 35.17 D 4937 D Stock Option (Right To Buy) 10.85 2019-03-05 4 M 0 1150 0 D 2023-05-15 Common Stock 1150.0 0 D Stock Option (Right To Buy) 13.1 2019-03-05 4 M 0 18750 13.10 D 2027-06-02 Common Stock 18750.0 6250 D Stock Option (Right To Buy) 11.23 2019-03-05 4 M 0 6300 11.23 D 2027-01-02 Common Stock 6300.0 6300 D Stock Option (Right To Buy) 490.8 2021-04-27 Common Stock 74.0 74 D Stock Option (Right To Buy) 218.4 2022-01-10 Common Stock 21.0 21 D Stock Option (Right To Buy) 27.05 2024-01-28 Common Stock 3369.0 3369 D Stock Option (Right To Buy) 40.45 2024-09-23 Common Stock 4688.0 4688 D Stock Option (Right To Buy) 51.0 2025-01-02 Common Stock 17800.0 17800 D Stock Option (Right To Buy) 30.86 2026-01-03 Common Stock 11000.0 11000 D Stock Option (Right To Buy) 18.01 2028-01-02 Common Stock 40000.0 40000 D Stock Option (Right To Buy) 33.02 2029-01-21 Common Stock 42500.0 42500 D Stock Option (Right To Buy) 33.02 2029-01-21 Common Stock 10100.0 10100 D The transactions reported in this Form 4 were effected pursuant to a written Rule 10b5-1 plan. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $34.29 to $34.98 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $35.00 to $35.60 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $34.29 to $34.94 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $34.96 to $35.40 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $34.06 to $34.99 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $35.00 to $35.71 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $34.96 to $35.44 per share. The reporting person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Currently exercisable. This option was granted on June 2, 2017, and vests over two years, with 50% of the shares underlying the option vesting on June 2, 2018, and an additional 12.5% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on September 2, 2018. This option was granted on January 3, 2017, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2018, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2018. This option was granted on January 4, 2016 and vests over four years, with 25% of the shares underlying the option vested on January 4, 2017, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 4, 2017. This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019. This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020. This option was granted on January 22, 2019 and vests over four years, with 50% of the shares underlying the option vesting on January 22, 2022, and the remaining 50% of the original number of shares underlying the option vesting on January 22, 2023. Avraham S. Adler, attorney-in-fact 2019-03-07